aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-11-10 20:23Core Viewpoint - A new class action lawsuit has been filed against aTyr Pharma, Inc. and its executives, expanding the alleged class period for investors who suffered losses from November 7, 2024, to September 12, 2025, due to misleading statements about the drug Efzofitimod [1][2][4]. Group 1: Class Action Details - The lawsuit, King v. aTyr Pharma Inc., seeks to represent all individuals and entities that acquired aTyr Pharma securities during the expanded class period [2]. - The previous class period began in January 2025, making this expansion significant for investors who purchased shares in late 2024 [2]. - The lead plaintiff deadline for the class action is set for December 8, 2025 [4]. Group 2: Allegations Against aTyr Pharma - The allegations center around aTyr's Phase 3 clinical trial, EFZO-FIT, which aimed to evaluate the efficacy of Efzofitimod in patients with pulmonary sarcoidosis [5]. - Executives from aTyr reportedly made overly positive statements about the study's design and its potential to reduce steroid dependency among patients [6]. - The lawsuit claims that aTyr concealed material adverse facts regarding the drug's efficacy, leading to securities law violations [7]. Group 3: Market Reaction and Investigation - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a dramatic stock price drop from $6.03 to $1.02, an 83.2% decline in one day [8][9]. - Hagens Berman, a prominent shareholders rights firm, is investigating whether aTyr misled investors about the drug's data and trial design while promoting its multi-billion-dollar market opportunity [10].